Published articles

Published articles 4 records found  Search took 0.01 seconds. 
1.
4 p, 1.4 MB Hidden costs of antiretroviral treatment : the public health efficiency of drug packaging / Andreu-Crespo, Àngels (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Llibre, Josep M (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ; Cardona-Peitx, Glòria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Sala-Piñol, Ferran (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Clotet, Bonaventura (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida) ; Bonafont-Pujol, Xavier (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol. Departament de Farmàcia)
While the overall percentage of unused antiretroviral medicines returned to the hospital pharmacy is low, their cost is quite high. Adverse events, treatment failure, pharmacokinetic interactions, pregnancy, or treatment simplification are common reasons for unplanned treatment changes. [...]
2015 - 10.2147/DDDT.S87075
Drug Design, Development and Therapy, Vol. 9 (august 2015) , p. 4287-4290  
2.
12 p, 646.0 KB Randomized, open-label, blinded-endpoint, crossover, single-dose study to compare the pharmacodynamics of torasemide-PR 10 mg, torasemide-IR 10 mg, and furosemide-IR 40 mg, in patients with chronic heart failure / Ballester, Maria Rosa (Institut d'Investigació Biomèdica Sant Pau) ; Roig, Eulàlia (Institut d'Investigació Biomèdica Sant Pau) ; Gich Saladich, Ignasi (Institut d'Investigació Biomèdica Sant Pau) ; Puntes, Montse (Institut d'Investigació Biomèdica Sant Pau) ; Delgadillo, Joaquín (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ; Santos, Benjamín (Ferrer Internacional, S.A.) ; Antonijoan Arbós, Rosa Ma. (Rosa María) (Institut d'Investigació Biomèdica Sant Pau) ; Universitat Autònoma de Barcelona
Diuretics are the primary treatment for the management of chronic heart failure (HF) symptoms and for the improvement of acute HF symptoms. The rate of delivery to the site of action has been suggested to affect diuretic pharmacodynamics. [...]
2015 - 10.2147/DDDT.S86300
Drug Design, Development and Therapy, Vol. 9 (august 2015) , p. 4291-4302  
3.
12 p, 478.7 KB Modeling the longitudinal latent effect of pregabalin on self-reported changes in sleep disturbances in outpatients with generalized anxiety disorder managed in routine clinical practice / Ruiz, Miguel A (Universidad Autónoma de Madrid) ; Álvarez, Enrique (Álvarez Martínez) (Institut d'Investigació Biomèdica Sant Pau) ; Carrasco, Jose L (Hospital Clínico San Carlos) ; Olivares, José M (Hospital Meixoeiro, Complejo Hospitalario Universitario, Vigo) ; Pérez, María (Medical Department, Pfizer, S.L.U.) ; Rejas, Javier (Health Economics and Outcomes Research Department, Pfizer, S.L.U.) ; Universitat Autònoma de Barcelona. Departament de Psiquiatria
Anxiety disorders are among the most common psychiatric illnesses, with generalized anxiety disorder (GAD) being one of the most common. Sleep disturbances are highly prevalent in GAD patients. While treatment with pregabalin has been found to be associated with significant improvement in GAD-related sleep disturbance across many controlled clinical trials, mediational analysis has suggested that a substantial portion of this effect could be the result of a direct effect of pregabalin. [...]
2015 - 10.2147/DDDT.S88238
Drug Design, Development and Therapy, Vol. 9 (august 2015) , p. 4329-4340  
4.
7 p, 216.6 KB Profile of omalizumab in the treatment of chronic spontaneous urticaria / Labrador-Horrillo, Moises (Hospital Universitari Vall d'Hebron) ; Ferrer, Marta (Clínica Universidad de Navarra) ; Universitat Autònoma de Barcelona. Departament de Medicina
Chronic spontaneous urticaria (CSU) is a disease with significant morbidity and relative prevalence that has important effects on the quality of life (QoL) of those who suffer from it. Omalizumab is a recombinant humanized anti-immunoglobulin E (IgE) antibody that binds to the Cε3 domain of the IgE heavy chain and prevents it from binding to its high-affinity receptor FcεRI. [...]
2015 - 10.2147/DDDT.S56004
Drug Design, Development and Therapy, Vol. 9 (august 2015) , p. 4909-4915  

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.